skip to Main Content

Assay Development

Our capabilities include assay feasibility, reagent sourcing and qualification, development, optimization, and sample analysis. Whether it is pharmacokinetic, immunogenicity or biomarker analysis, we provide rapid turnaround and consistent results for your projects. Our team has extensive experience in ELISA and enzymatic assays and the Meso Scale Discovery™ electrochemiluminesence platform. Immunogenicity assays for vaccines and biologics are our specialty. We can perform your in vivo studies and then do sample analysis using serology assays that we have developed for your project.

Assays are developed using best practices that will allow them to be adapted for GLP use in the future. IBT Bioservices can source or develop the critical reagents necessary for your assays. To ensure data integrity, we perform double documentation QC for all assays. Through our network of partners, we can transition your studies to be run under GLP as needed.

Working With Our Clients

At IBT we build close scientific partnerships with our clients that instill trust and confidence. We take pride in our ability to deliver confidential, accurate and on-time results. We take a milestone approach to customize any project to your specific needs:

  • Assay Feasibility
  • Assay Development/Transfer
  • Non-GLP Sample Analysis

Assay Types

  • ELISA
  • HAI
  • PK Immunoassays
  • Receptor Neutralization
  • Serological Assays
  • Enzyme Assays
  • Immunogenicity Testing
Back To Top
×Close search
Search
Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.

Alpha (UK) – B. 1.1.7 / 501Y.V1

amino acid mutations: del69–70 HV, del144 Y, N501Y, A570D, D614G, P681H, T761I, S982A, D1118H

Beta (South Africa) – B.1.351

amino acid mutations: K417N, E484K, N501Y, D614G, A701V

Gamma (Brazil) – P.1

amino acid mutations: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I

Epsilon (Ca, USA) B.1.427

amino acid mutations: L452R, D614G

SARS-CoV-2 Parental Strain Wild Type (Wuhan)
SARS-CoV-2 D614G Variant

amino acid mutations: D614G

Epsilon (Ca, USA) B.1.429

amino acid mutations: S13I, W152C, L452R, D614G

SARS-CoV-2 Delta Variant

amino acid mutations: L452R, E484Q